0001013762-14-000832.txt : 20140723 0001013762-14-000832.hdr.sgml : 20140723 20140723160527 ACCESSION NUMBER: 0001013762-14-000832 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140721 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year FILED AS OF DATE: 20140723 DATE AS OF CHANGE: 20140723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DelMar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001498382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990360497 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54801 FILM NUMBER: 14988867 BUSINESS ADDRESS: STREET 1: SUITE 720-999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (604) 629-5989 MAIL ADDRESS: STREET 1: SUITE 720-999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 FORMER COMPANY: FORMER CONFORMED NAME: Berry Only Inc. DATE OF NAME CHANGE: 20100805 8-K 1 form8k.htm DELMAR PHARMACEUTICALS, INC. FORM 8-K form8k.htm
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 21, 2014

DELMAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
  
  000-54801
  
  99-0360497
 (State or Other Jurisdiction of Incorporation)  
  
 (Commission File Number)
  
(I.R.S. Employer Identification Number)
         
 
Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of principal executive offices)

(604) 629-5989
 (Registrant's telephone number, including area code)

  Copies to:
Gregory Sichenzia, Esq.
Jeff Cahlon, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725
 

 (Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
 
Item 5.03                      Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 21, 2014, the Board of Directors of DelMar Pharmaceuticals, Inc. (the “Company”) approved a change of the Company’s fiscal year from December 31 to June 30.  In accordance with certain rules promulgated under the Securities Exchange Act of 1934, as amended, the Company will file a Transition Report on Form 10-K within the time period prescribed by such rules.

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
DELMAR PHARMACEUTICALS, INC.
  
       
Dated: July 23, 2014
By:
/s/ Jeffrey Bacha
  
   
Name: Jeffrey Bacha
  
   
Title: Chief Executive Officer